Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide.
Oka T, Hatano K, Tani M, Yoshimura A, Horibe Y, Liu Y, Sassi N, Okuda Y, Yamamoto A, Uemura T, Yamamichi G, Ishizuya YU, Yamamoto Y, Kato T, Kawashima A, Fujita K, Nonomura N. Oka T, et al. Among authors: ishizuya yu. Cancer Diagn Progn. 2024 Nov 3;4(6):706-714. doi: 10.21873/cdp.10385. eCollection 2024 Nov-Dec. Cancer Diagn Progn. 2024. PMID: 39502601 Free PMC article.
GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment.
Yamamichi G, Kato T, Arakawa N, Ino Y, Ujike T, Nakano K, Koh Y, Motoyama Y, Outani H, Myoba S, Ishizuya Y, Yamamoto Y, Hatano K, Kawashima A, Fukuhara S, Uemura H, Okada S, Morii E, Nonomura N, Uemura M. Yamamichi G, et al. Among authors: ishizuya y. Biomark Res. 2024 Nov 25;12(1):147. doi: 10.1186/s40364-024-00695-6. Biomark Res. 2024. PMID: 39587633
Bacterial information in serum extracellular vesicles reflects the inflammation of adherent perinephric fat.
Uemura T, Kawashima A, Jingushi K, Motooka D, Saito T, Sassi N, Horibe Y, Yamamoto A, Liu Y, Tani M, Yoshimura A, Oka T, Okuda Y, Yamamichi G, Ishizuya Y, Yamamoto Y, Kato T, Hatano K, Tsujikawa K, Wada H, Nonomura N. Uemura T, et al. Among authors: ishizuya y. Cancer Sci. 2024 Nov 20. doi: 10.1111/cas.16410. Online ahead of print. Cancer Sci. 2024. PMID: 39566543 Free article.
Serum D-asparagine concentration adjusted for eGFR could serve as a novel screening tool for urothelial carcinoma.
Yamamoto A, Kawashima A, Sakai S, Mita M, Sassi N, Inoguchi S, Horibe Y, Yoshimura A, Tani M, Yutong L, Okuda Y, Oka T, Uemura T, Yamamichi G, Ishizuya Y, Hayashi T, Yamamoto Y, Kato T, Hatano K, Kakuta Y, Imamura R, Takahara S, Kimura T, Nonomura N. Yamamoto A, et al. Among authors: ishizuya y. Biochem Biophys Res Commun. 2024 Nov 12;733:150701. doi: 10.1016/j.bbrc.2024.150701. Epub 2024 Sep 14. Biochem Biophys Res Commun. 2024. PMID: 39326256 Free article.
Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan.
Yoshimura A, Kato T, Nakai Y, Tsujihata M, Toyoda S, Sato M, Matsuzaki K, Nakata W, Takao T, Inoguchi S, Okuda Y, Yamamichi G, Ishizuya Y, Yamamoto Y, Hatano K, Kawashima A, Takada S, Inoue H, Nishimura K, Miyake O, Fujita K, Nakayama M, Nishimura K, Nonomura N. Yoshimura A, et al. Among authors: ishizuya y. Int J Clin Oncol. 2024 Dec;29(12):1916-1924. doi: 10.1007/s10147-024-02612-1. Epub 2024 Sep 2. Int J Clin Oncol. 2024. PMID: 39222148
Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.
Kawashima A, Ishizuya Y, Yamamoto Y, Kato T, Hatano K, Nonomura N. Kawashima A, et al. Among authors: ishizuya y. Int J Clin Oncol. 2024 Aug;29(8):1096-1104. doi: 10.1007/s10147-024-02526-y. Epub 2024 Jun 8. Int J Clin Oncol. 2024. PMID: 38850448 Free PMC article. Review.
42 results